AU680628B2 - Novel uses of IL-4 and/or IL-10, and antibodies against the same - Google Patents

Novel uses of IL-4 and/or IL-10, and antibodies against the same Download PDF

Info

Publication number
AU680628B2
AU680628B2 AU50108/93A AU5010893A AU680628B2 AU 680628 B2 AU680628 B2 AU 680628B2 AU 50108/93 A AU50108/93 A AU 50108/93A AU 5010893 A AU5010893 A AU 5010893A AU 680628 B2 AU680628 B2 AU 680628B2
Authority
AU
Australia
Prior art keywords
cells
pct
cell
line
document
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU50108/93A
Other languages
English (en)
Other versions
AU5010893A (en
Inventor
Robert Coffman
Jan E De Vries
Rene De Waal Malefyt
Fiona Powrie
Donna Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU5010893A publication Critical patent/AU5010893A/en
Application granted granted Critical
Publication of AU680628B2 publication Critical patent/AU680628B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
AU50108/93A 1992-08-20 1993-08-18 Novel uses of IL-4 and/or IL-10, and antibodies against the same Ceased AU680628B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US932900 1992-08-20
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US93395092A 1992-08-21 1992-08-21
US93346292A 1992-08-21 1992-08-21
US93341992A 1992-08-21 1992-08-21
US933462 1992-08-21
US933950 1992-08-21
US933419 1992-08-21
PCT/US1993/007646 WO1994004180A2 (en) 1992-08-20 1993-08-18 Novel uses of il-4 and/or il-10, and antibodies against the same

Publications (2)

Publication Number Publication Date
AU5010893A AU5010893A (en) 1994-03-15
AU680628B2 true AU680628B2 (en) 1997-08-07

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50108/93A Ceased AU680628B2 (en) 1992-08-20 1993-08-18 Novel uses of IL-4 and/or IL-10, and antibodies against the same

Country Status (22)

Country Link
EP (2) EP0801951A3 (enExample)
JP (1) JP3494647B2 (enExample)
KR (1) KR0170037B1 (enExample)
CN (1) CN1090204A (enExample)
AT (1) ATE162947T1 (enExample)
AU (1) AU680628B2 (enExample)
CA (1) CA2142861C (enExample)
CZ (1) CZ283488B6 (enExample)
DE (1) DE69316921T2 (enExample)
DK (1) DK0671933T3 (enExample)
ES (1) ES2111769T3 (enExample)
FI (1) FI950697A7 (enExample)
GR (1) GR3026635T3 (enExample)
HU (1) HU220103B (enExample)
IL (1) IL106725A (enExample)
MX (1) MX9305054A (enExample)
MY (1) MY111402A (enExample)
PL (1) PL307566A1 (enExample)
RU (1) RU2120802C1 (enExample)
SK (1) SK21195A3 (enExample)
TW (1) TW243415B (enExample)
WO (1) WO1994004180A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6000894A (en) * 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
EE03451B1 (et) 1994-07-05 2001-06-15 Steeno Research Group A/S Immunomodulaatorid
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
JPH11501506A (ja) * 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (en) * 1995-08-01 1997-02-05 Institut Pasteur Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
KR20000005539A (ko) * 1996-04-17 2000-01-25 패트릭 티. 프렌더가스트 Dhea복합요법
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
ATE259829T1 (de) * 1998-10-20 2004-03-15 Vlaams Interuniv Inst Biotech Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
DE60017115T2 (de) 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
DK2295968T3 (da) * 1999-12-03 2012-12-17 Baxter Healthcare Sa Pyrogenicitetsprøve til anvendelse i forbindelse med automatiserede immunanalysesystemer
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
RU2196605C2 (ru) * 2000-12-07 2003-01-20 Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Способ получения растворимых конъюгатов биологически активных веществ
RU2202363C2 (ru) * 2001-04-09 2003-04-20 Ершов Феликс Иванович Способ определения чувствительности живого организма и/или его клеток к воздействию вещества, поля или комбинации веществ и/или полей
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
WO2006130188A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic bifidobacteria
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
US20080254014A1 (en) * 2005-10-03 2008-10-16 Actogenix N V Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis
EP2066336B1 (en) * 2006-09-28 2012-09-19 Merck Sharp & Dohme Corp. Use of pegylated il-10 to treat cancer
CN101711158A (zh) 2007-02-01 2010-05-19 爱默思公司 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
RU2679889C2 (ru) * 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
DK3021873T3 (en) 2013-07-18 2018-12-17 Xalud Therapeutics Inc Composition for the treatment of inflammatory joint disease
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405980A1 (en) * 1989-06-28 1991-01-02 Schering Corporation Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same
AU3899893A (en) * 1992-04-06 1993-11-08 Isis Innovation Limited Compositions for the treatment of acute or chronic inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE116550T1 (de) * 1991-01-16 1995-01-15 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405980A1 (en) * 1989-06-28 1991-01-02 Schering Corporation Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same
AU3899893A (en) * 1992-04-06 1993-11-08 Isis Innovation Limited Compositions for the treatment of acute or chronic inflammation

Also Published As

Publication number Publication date
EP0801951A3 (en) 1998-05-20
FI950697L (fi) 1995-04-07
RU95108330A (ru) 1996-11-27
EP0671933B1 (en) 1998-02-04
CZ283488B6 (cs) 1998-04-15
PL307566A1 (en) 1995-05-29
FI950697A7 (fi) 1995-04-07
ATE162947T1 (de) 1998-02-15
MY111402A (en) 2000-04-29
RU2120802C1 (ru) 1998-10-27
MX9305054A (es) 1994-02-28
CN1090204A (zh) 1994-08-03
HU220103B (hu) 2001-10-28
CA2142861A1 (en) 1994-03-03
JPH08500362A (ja) 1996-01-16
IL106725A (en) 2000-12-06
ES2111769T3 (es) 1998-03-16
IL106725A0 (en) 1993-12-08
FI950697A0 (fi) 1995-02-16
DK0671933T3 (da) 1998-09-23
DE69316921D1 (de) 1998-03-12
DE69316921T2 (de) 1998-06-04
AU5010893A (en) 1994-03-15
CZ44195A3 (en) 1995-10-18
WO1994004180A3 (en) 1994-06-09
GR3026635T3 (en) 1998-07-31
KR950702841A (ko) 1995-08-23
EP0801951A2 (en) 1997-10-22
HK1004326A1 (en) 1998-11-20
CA2142861C (en) 2000-08-15
JP3494647B2 (ja) 2004-02-09
HUT70976A (en) 1995-11-28
WO1994004180A2 (en) 1994-03-03
EP0671933A1 (en) 1995-09-20
HU9500467D0 (en) 1995-04-28
TW243415B (enExample) 1995-03-21
SK21195A3 (en) 1996-10-02
KR0170037B1 (ko) 1999-02-01

Similar Documents

Publication Publication Date Title
AU680628B2 (en) Novel uses of IL-4 and/or IL-10, and antibodies against the same
Grabstein et al. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody.
Van Snick Interleukin-6: an overview
Hagenbaugh et al. Altered immune responses in interleukin 10 transgenic mice
Neighbors et al. A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon γ production
Palacios et al. IL3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo
Shankar et al. T cell and non-T cell compartments can independently determine resistance to Leishmania major.
US20180265846A1 (en) Chimeric antigen receptor anti-inflammatory cells and methods of use
JPH07508179A (ja) ヒトインターロイキン−１３
US5837293A (en) Use of interleukin-10 analogs for antagonists to treat endotoxin- or superantigen-induced toxicity
AU665042B2 (en) Suppressor and progenitor cells
KR100271197B1 (ko) 인터루킨-10동족체또는길항제를포함하는내독소-또는초항원유도된독성치료용의약제학적조성물
Rocha et al. Interleukin 2 receptor expression and interleukin 2 production in exponentially growing T cells: major differences between in vivo and in vitro proliferating T lymphocytes
US6319493B1 (en) Treatment of neoplastic disease with interleukin-10
NZ255757A (en) Compositions and methods for the use of il-4 and/or il-10 and antibodies against these cytokines
Dean et al. Pre-clinical toxicity of IL-4: A model for studying protein therapeutics
Schneider et al. Severe Graft‐Versus‐Host Disease in SCID Mice is Associated with a Decrease of Selective Donor Cell TCR Vβ Specificities and Increased Expression of IFN‐γ and IL‐4
Narula et al. New cytokines as potential drugs
Yang et al. Human Interleukin-15 Improves
Grabstein Inhibition of Murine B and T Lymphopoiesis In Vivo by an Anti-Interleukln 7 Monoclonal Antibody By Kenneth H. Grabstein, Thomas J. Waldschmidt,* Fred D. Finkelman,~ Bruce W. Hess, Alan R. Alpert, Norman E. Boiani, Anthony E. Namen, and Philip J. Morrissey
HK1004326B (en) Novel uses of il-10

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired